Position in GUTS
as of Jun 30, 2026
· filed Jul 21, 2026
Position Value
$2,382
+$1,008 QoQ
Shares Held
3,000
0.0% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#67
of 76 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in GUTS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Triumph Capital Management holds $2,971,996 across 21 Biotechnology names. GUTS ranks #14 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ELDN |
Eledon Pharmaceuticals, Inc.
|
303,443 | $1,195,565 | |
| 2 | INCY |
Incyte Corp
|
6,801 | $770,961 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
2,597 | $625,799 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
414 | $258,145 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
112 | $55,633 | |
| 6 | ARQT |
Arcutis Biotherapeutics, Inc.
|
900 | $23,598 | |
| 7 | RIGL |
Rigel Pharmaceuticals Inc
|
200 | $7,824 | |
| 8 | MRNA |
Moderna, Inc.
|
100 | $7,003 |
All Filings in GUTS
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,382 | 3,000 | Shares | Sole | 2026-07-21 | |
| 2026-03-31 | $1,374 | 3,000 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $6,600 | 3,000 | Shares | Sole | 2026-02-12 | |
| No filing history on record for this holder in this stock. | ||||||